These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 38542317)

  • 1. Prostaglandin Transporter and Dipeptidyl Peptidase-4 as New Pharmacological Targets in the Prevention of Acute Kidney Injury in Diabetes: An In Vitro Study.
    Gallego-Tamayo B; Santos-Aparicio Á; Yago-Ibáñez J; Muñoz-Moreno L; Lucio-Cazaña FJ; Fernández-Martínez AB
    Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dipeptidyl peptidase-4 inhibitor teneligliptin accelerates recovery from cisplatin-induced acute kidney injury by attenuating inflammation and promoting tubular regeneration.
    Iwakura T; Zhao Z; Marschner JA; Devarapu SK; Yasuda H; Anders HJ
    Nephrol Dial Transplant; 2019 Oct; 34(10):1669-1680. PubMed ID: 30624740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apoptosis and cell proliferation in proximal tubular cells exposed to apoptotic bodies. Novel pathophysiological implications in cisplatin-induced renal injury.
    García-Pastor C; Blázquez-Serra R; Bosch RJ; Lucio Cazaña FJ; Fernández-Martínez AB
    Biochim Biophys Acta Mol Basis Dis; 2019 Sep; 1865(9):2504-2515. PubMed ID: 31195118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intracellular prostaglandin E2 contributes to hypoxia-induced proximal tubular cell death.
    García-Pastor C; Benito-Martínez S; Bosch RJ; Fernández-Martínez AB; Lucio-Cazaña FJ
    Sci Rep; 2021 Mar; 11(1):7047. PubMed ID: 33782420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Dipeptidyl Peptidase-4 Inhibitor and Angiotensin-Converting Enzyme Inhibitor on Experimental Diabetic Kidney Disease.
    Al Tuhaifi T; Zhong J; Yang HC; Fogo AB
    Lab Invest; 2024 Feb; 104(2):100305. PubMed ID: 38109999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intracellular prostaglandin E2 mediates cisplatin-induced proximal tubular cell death.
    Fernández-Martínez AB; Benito Martínez S; Lucio Cazaña FJ
    Biochim Biophys Acta; 2016 Feb; 1863(2):293-302. PubMed ID: 26658718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological profiles of gemigliptin (LC15-0444), a novel dipeptidyl peptidase-4 inhibitor, in vitro and in vivo.
    Kim SH; Jung E; Yoon MK; Kwon OH; Hwang DM; Kim DW; Kim J; Lee SM; Yim HJ
    Eur J Pharmacol; 2016 Oct; 788():54-64. PubMed ID: 27298192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of dipeptidyl peptidase-4 inhibitors on cisplatin-induced acute nephrotoxicity in cancer patients with diabetes mellitus: A retrospective study.
    Iwakura T; Fukasawa H; Kitamura A; Ishibuchi K; Yasuda H; Furuya R
    PLoS One; 2020; 15(2):e0229377. PubMed ID: 32084231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes.
    Kodera R; Shikata K; Takatsuka T; Oda K; Miyamoto S; Kajitani N; Hirota D; Ono T; Usui HK; Makino H
    Biochem Biophys Res Commun; 2014 Jan; 443(3):828-33. PubMed ID: 24342619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin.
    Kanasaki K
    Clin Sci (Lond); 2018 Feb; 132(4):489-507. PubMed ID: 29491123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Odds of Acute Kidney Injury in Patients Receiving Dipeptidyl Peptidase 4 Inhibitors: A National Cohort Study Within the Department of Veterans Affairs.
    Sutton SS; Magagnoli J; Cummings TH; Hardin JW
    Clin Transl Sci; 2019 Nov; 12(6):698-703. PubMed ID: 31420973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucose-independent renoprotective mechanisms of the tissue dipeptidyl peptidase-4 inhibitor, saxagliptin, in Dahl salt-sensitive hypertensive rats.
    Uchii M; Kimoto N; Sakai M; Kitayama T; Kunori S
    Eur J Pharmacol; 2016 Jul; 783():56-63. PubMed ID: 27063445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Ameliorates Endothelial Inflammation and Microvascular Thrombosis in a Sepsis Mouse Model.
    Wang SC; Wang XY; Liu CT; Chou RH; Chen ZB; Huang PH; Lin SJ
    Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dipeptidyl peptidase IV inhibitors and ischemic myocardial injury.
    Yoon AH; Ye Y; Birnbaum Y
    J Cardiovasc Pharmacol Ther; 2014 Sep; 19(5):417-25. PubMed ID: 24607763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes.
    Singh S; Roy S; Sethi S; Benjamin B; Sundaram S; Khanna V; Kandalkar SR; Pal C; Kant R; Patra AK; Rayasam G; Mittra S; Saini KS; Paliwal J; Chugh A; Ahmed S; Sattigeri J; Cliff I; Ray A; Bansal VS; Bhatnagar PK; Davis JA
    Eur J Pharmacol; 2011 Feb; 652(1-3):157-63. PubMed ID: 20540938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement in Mortality and End-Stage Renal Disease in Patients With Type 2 Diabetes After Acute Kidney Injury Who Are Prescribed Dipeptidyl Peptidase-4 Inhibitors.
    Chen CY; Wu VC; Lin CJ; Lin CS; Pan CF; Chen HH; Lin YF; Huang TM; Chen L; Wu CJ;
    Mayo Clin Proc; 2018 Dec; 93(12):1760-1774. PubMed ID: 30343892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver, renal, genitourinary and diabetic ketoacidosis risks among new users of empagliflozin versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: Post-authorization safety study based on multinational cohorts.
    Rebordosa C; Thomsen RW; Tave AK; Madsen M; Beachler DC; Martinez D; Garcia-Esteban R; Plana E; Tormos A; Farsani SF; Perez-Gutthann S; Pladevall-Vila M
    Diabetes Obes Metab; 2024 Apr; 26(4):1291-1304. PubMed ID: 38234181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective effects of DPP-4 inhibitor on podocyte injury in glomerular diseases.
    Kubo A; Hidaka T; Nakayama M; Sasaki Y; Takagi M; Suzuki H; Suzuki Y
    BMC Nephrol; 2020 Sep; 21(1):402. PubMed ID: 32948146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats.
    Liu WJ; Xie SH; Liu YN; Kim W; Jin HY; Park SK; Shao YM; Park TS
    J Pharmacol Exp Ther; 2012 Feb; 340(2):248-55. PubMed ID: 22025647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Network Meta-Analysis of Novel Glucose-Lowering Drugs on Risk of Acute Kidney Injury.
    Zhao M; Sun S; Huang Z; Wang T; Tang H
    Clin J Am Soc Nephrol; 2020 Dec; 16(1):70-78. PubMed ID: 33376101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.